- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04414202
Observational Study of Intra-operative Partial Irradiation of Invasive Ductal Breast Carcinomas With a Good Prognosis (INTRA-OBS)
Due to screening, T1N0 early-stage breast cancer now accounts for more than 50% of the tumors diagnosed in France. The prognosis of these tumors is good, even excellent in women ≥ 65 years of age, with specific survival of 98% at 5 years.
The treatment of these tumors combines breast-conserving surgery and external whole breast irradiation for 6.5 weeks.
A true de-escalation of treatment is taking place with these tumors, both surgically and medically. Surgery therefore now prefers breast-conserving methods in combination with exeresis of the sentinel lymph node only. In the same way, in many international studies, radiotherapy has been evaluating the possibility of reducing both:
- the irradiation volume at the excision site (partial irradiation)
- the duration of this irradiation (accelerated radiotherapy)
Between 2004 and 2007, the CRLC [Regional Anti-Cancer Center] evaluated the feasibility and the oncological results of intra-operative partial irradiation via a phase II study in women 65 years of age and older with T1N0M0 hormone-sensitive tumors with a good prognosis.
From 2010 to 2013, the ICM carried out an observational study of these tumors with an excellent prognosis.
In July 2009, the American Society for Radiation Oncology (ASTRO) published a consensus statement with specific recommendations and indications for accelerated partial breast irradiation (APBI).
This APBI technique has been developing in France over the past 5 years within the framework of clinical studies and in compliance with the 2012 recommendations of the French National Cancer Institute. This APBI can be given by 3D external radiotherapy or, as in this study, by intra-operative radiotherapy (IORT) in order to obtain optimal precision and spare as much of the surrounding healthy tissue as possible.
The Investigator therefore propose a cohort study to prospectively analyze the results of this technique applied to the indications strictly defined by the ASTRO.
Study Overview
Status
Conditions
Detailed Description
after registration, particpants have as treatment "combination extended tumorectomy with axillary dissection (sentinel lymph node) in addition to 20 Gy of per-operative partial irradiation at the tumor site.
follow up after this treatment during 5 years
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Herault
-
Montpellier, Herault, France, 34398
- ICM Val d'Aurelle
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women 60 years of age or older,
Histologically proven invasive ductal breast cancer or of a histologically favorable sub-type (mucinous, tubular or colloid),
-. Unifocal tumor,
- T1 (diameter ≤ 20 mm),
- N0 (pN0 or pNi+),
- M0,
- Gland exeresis margins ≥ 2 mm,
- Estrogen receptor positive,
- Information and non-opposition of the patient.
Exclusion Criteria:
-. Inflammatory breast cancer,
- Associated peri-tumoral lymphatic emboli
- Associated extensive intra-ductal component
- Invasive lobular carcinoma
- Pure ductal carcinoma in situ,
- Sarcoma or lymphoma-type non-epithelial tumor
- Synchronous bilateral breast cancer,
- Any prior neo-adjuvant treatment: radiotherapy, chemotherapy, hormone therapy
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
1 GROUP
Patient with an Invasive breast cancer with a good prognosis that is accessible to breast-conserving surgery. The treatment combines extended tumorectomy with axillary dissection (sentinel lymph node) in addition to 20 Gy of per-operative partial irradiation at the tumor Follow up after this treatment will scheduled 10 years |
All patients will have local excision of the primary tumor following appropriate clinical work-up.
Surgery will be done according to usual local practice with a complete excision of the tumor.
The aim of the local excision should be to achieve a minimum free margin of 2 mm whilst maintaining a good cosmetic outcome.
20 Gy of per-operative partial irradiation at the tumor site during the surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local intra-mammary relapse rate
Time Frame: post surgery : 3 weeks, every 6 months during 5 years and annually during 5 years (10 years in total)
|
The local relapse rate, defined as the number of intramammary relapses in the treated breast (regardless of quadrant and including skin), appreciated at 5 years and 10 years.
It will be assessed according to the recommendations applied to the Centre
|
post surgery : 3 weeks, every 6 months during 5 years and annually during 5 years (10 years in total)
|
Local intra-mammary relapse rate
Time Frame: post surgery : 3 weeks, every 6 months during 5 years and annually during 5 years (10 years in total)
|
The local relapse rate, defined as the number of intramammary relapses in the homolateral lymph node, appreciated at 5 years and 10 years.
It will be assessed according to the recommendations applied to the Centre
|
post surgery : 3 weeks, every 6 months during 5 years and annually during 5 years (10 years in total)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cosmetic results
Time Frame: post surgery : 3 weeks, 6 months and 12 months
|
Evaluation of the cosmetic result of questionnaire (0 from 10)
|
post surgery : 3 weeks, 6 months and 12 months
|
Survival without metastatic relapse
Time Frame: post surgery : 3 weeks, every 6 months during 5 years and annually during 5 years (10 years in total)
|
Study of survival without metastatic relapse, of overall survival, of specific survival
|
post surgery : 3 weeks, every 6 months during 5 years and annually during 5 years (10 years in total)
|
patients' satisfaction towards the treatment
Time Frame: post surgery : 3 weeks, 6 months and 12 months
|
Satisfaction will be measured using the Likert scale (0 no satisfy to 10: strongly satisfy)
|
post surgery : 3 weeks, 6 months and 12 months
|
Impact of the accelerated treatment on the maintenance of autonomy in elderly patients
Time Frame: post surgery : 3 weeks, 6 months and 12 months
|
Assessment of the impact of this accelerated treatment on maintaining the autonomy of the subject by the use of geriatric scale (ADL, IADL).
|
post surgery : 3 weeks, 6 months and 12 months
|
Collaborators and Investigators
Investigators
- Study Chair: LEMANSKI Claire, DR, ICM Val d'Aurelle DRCI
Publications and helpful links
General Publications
- Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002 Oct 17;347(16):1233-41. doi: 10.1056/NEJMoa022152.
- Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002 Oct 17;347(16):1227-32. doi: 10.1056/NEJMoa020989.
- Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, Julian TB, Marks LB, Todor DA, Vicini FA, Whelan TJ, White J, Wo JY, Harris JR. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). J Am Coll Surg. 2009 Aug;209(2):269-77. doi: 10.1016/j.jamcollsurg.2009.02.066. Epub 2009 Apr 24. No abstract available.
- Dubois JB, Hay M, Gely S, Saint-Aubert B, Rouanet P, Pujol H. IORT in breast carcinomas. Front Radiat Ther Oncol. 1997;31:131-7. doi: 10.1159/000061160. No abstract available.
- Lemanski C, Azria D, Thezenas S, Gutowski M, Saint-Aubert B, Rouanet P, Fenoglietto P, Ailleres N, Dubois JB. Intraoperative radiotherapy given as a boost for early breast cancer: long-term clinical and cosmetic results. Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1410-5. doi: 10.1016/j.ijrobp.2005.10.025. Epub 2006 Jan 25.
- Lemanski C, Azria D, Gourgon-Bourgade S, Gutowski M, Rouanet P, Saint-Aubert B, Ailleres N, Fenoglietto P, Dubois JB. Intraoperative radiotherapy in early-stage breast cancer: results of the montpellier phase II trial. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):698-703. doi: 10.1016/j.ijrobp.2009.02.039. Epub 2009 May 23.
- Vinh-Hung V, Verschraegen C. Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst. 2004 Jan 21;96(2):115-21. doi: 10.1093/jnci/djh013.
- Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 Dec 17;366(9503):2087-106. doi: 10.1016/S0140-6736(05)67887-7.
- Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad WJ, Oei SB, Warlam-Rodenhuis CC, Pierart M, Collette L. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007 Aug 1;25(22):3259-65. doi: 10.1200/JCO.2007.11.4991. Epub 2007 Jun 18.
- van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, van der Schueren E, Helle PA, van Zijl K, Bartelink H. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000 Jul 19;92(14):1143-50. doi: 10.1093/jnci/92.14.1143.
- Grosclaude P, Colonna M, Hedelin G, Tretarre B, Arveux P, Lesec'h JM, Raverdy N, Sauvage-Machelard M. Survival of women with breast cancer in france: variation with age, stage and treatment. Breast Cancer Res Treat. 2001 Nov;70(2):137-43. doi: 10.1023/a:1012974728007.
- Vlastos G, Mirza NQ, Meric F, Hunt KK, Kuerer HM, Ames FC, Ross MI, Buchholz TA, Hortobagyi GN, Singletary SE. Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experience. Cancer. 2001 Sep 1;92(5):1092-100. doi: 10.1002/1097-0142(20010901)92:53.0.co;2-p.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009/OBS-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Invasive Breast Cancer
-
University Health Network, TorontoCompletedBreast Cancer Invasive Nos | Primary Invasive Breast CancerCanada
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Hoffmann-La Roche; Brigham and Women's...TerminatedStage I Breast Cancer | Stage II Breast Cancer | Invasive Breast Carcinoma | Stage III Breast Cancer | Primary Invasive Breast CancerUnited States
-
Dana-Farber Cancer InstitutePfizerCompletedBreast Cancer Stage IV | Unresectable Locally Advanced Invasive Breast Cancer | Metastatic Invasive Breast CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast CarcinomaUnited States, Puerto Rico
-
H. Lee Moffitt Cancer Center and Research InstituteAmgenActive, not recruitingBreast Cancer | Invasive Breast Carcinoma | Invasive Ductal Breast Carcinoma | Ductal CarcinomaUnited States
-
University of Illinois at ChicagoRecruitingBreast Cancer Female | Breast Cancer InvasiveUnited States
-
Stanford UniversityNational Institutes of Health (NIH)RecruitingBreast Cancer | Breast Cancer Non-invasive Breast CancerUnited States
-
University of California, IrvineCompletedInvasive Breast Cancer | Incident Breast Cancer
-
University Medical Center GroningenMartini Hospital GroningenRecruitingBreast Cancer | Breast Cancer InvasiveNetherlands
-
RenJi HospitalRecruitingBreast Cancer InvasiveChina
Clinical Trials on tumorectomy with axillary dissection (sentinel lymph node)
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedBreast Neoplasm Female
-
Gangnam Severance HospitalCompletedNeoadjuvant Chemotherapy | Micrometastases
-
University Hospital OstravaSilesian Hospital in OpavaCompletedBreast CancerCzechia
-
Fudan UniversityRecruiting
-
Institut du Cancer de Montpellier - Val d'AurelleCompletedBreast CancerFrance
-
Xiangyun ZongRecruitingBreast Cancer LymphedemaChina
-
Shandong Cancer Hospital and InstituteCompleted
-
Gangnam Severance HospitalCompletedBreast Cancer | Sentinel Lymph Node | Breast MRI | Neoadjuvant Systemic Therapy
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedStage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Breast Carcinoma Metastatic in Lymph Node | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7United States